Abstract
Six fasting male subjects (20–32 years of age) received an oral tablet and an IV 1.0-mg dose of alprazolam in a crossover-design study. Alprazolam plasma concentration in multiple samples during 36 h after dosing was determined by electron-capture gas-liquid chromatography. Psychomotor performance tests, digit-symbol substitution (DSS), and perceptual speed (PS) were administered at 0, 1.25, 2.25, 5.0, and 12.5 h. Sedation was assessed by the subjects and by an observer using the Stanford Sleepiness Scale and a Nurse Rating Sedation Scale (NRSS), respectively. Mean kinetic parameters after IV and oral alprazolam wre as follows: volume of distribution (V d) 0.72 and 0.84 l/kg; elimination half-life (t 1/2) 11.7 and 11.8 h; clearance (Cl) 0.74 and 0.89 ml/min/kg. There were no significant differences between IV and oral alprazolam in V d, t 1/2, or area under the curve. The mean fraction absorbed after oral administration was 0.92. Performance on PS and DSS tests was impaired at 1.25 and 2.5 h, but had returned to baseline at 5.0 h for both treatments. Onset of sedation was rapid after IV administration and the average time of peak sedation was 0.48 h. Sedation scores were significantly lower during hour 1 after oral administration than after IV, but were not significantly different at later times. Alprazolam is fully available after oral administration and kinetic parameters are not affected by route of administration. With the exception of rapidity of onset, the pharmacodynamic profiles of IV and oral alprazolam are very similar after a 1.0-mg dose.
Article PDF
Similar content being viewed by others
References
Arendt R, Greenblatt D, DeJong R, Bonin J, Abernethy D, Ehrenberg B, Giles H, Sellers E, Shader R (1983) In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther 227:98–106
Chouinard G, Annable L, Fontaine R, Solyom L (1982) Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 77:229–233
Cohn JB (1981) Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J Clin Psychiatry 42:347–351
Dement W, Seidel W, Carskadon M (1982) Daytime alertness, insomnia, and benzodiazepines. Sleep 5:28–45
Eberts FS, Philopoulos Y, Reineke LM, Vliek RW (1980) Disposition of 14C-alprazolam. A new anxiolytic-antidepressant in man. Pharmacologist 22:279 (abstract)
Ellinwood EH, Linnoila M, Easler ME, Molter DW (1983) Profile of acute tolerance to three sedative anxiolytics. Psychopharmacology 79:137–141
Fabre LF, McLendon DM (1980) A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Ther Res 27:474–482
Feighner JP, Aden GC, Fabre LF (1983) Multicenter double-blind safety and efficacy comparison of alprazolam, imipramine and placebo in the treatment of major depressive disorder. JAMA 249:3057–3064
Greiss KC, Fogari R (1980) Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety. J Clin Pharmacol 20:693–699
Greenblatt DJ, Shader RI, Franke K, MacLaughlin DS, Harmatz JS, Divoll M, Werner A, Woo E (1979) Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans. J Pharm Sci 68:57–63
Greenblatt DJ, Divoll M, Moschitto LJ, Shader RI (1981) Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr 225:202–207
Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI (1983) Alprazolams kinetics in the elderly. Arch Gen Psychiatry 40:287–290
Hoddes E, Zarcome V, Smythe H, Phillips R, Dement WC (1973) Quantification of sleepiness: A new approach. Psychophysiology 10:431–436
Johnson LC, Chernik DA (1982) Sedative-hypnotic and human performance. Psychopharmacology 76:101–113
Lepik IE, Derivan AT, Homan RW, Walker J, Ramsay E, Patrick B (1983) Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249:1452–1454
Sedman A, Wagner JG (1976) CSTRIP, a Fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65:1006–1010
Smith RB, Gwilt PR, Wright CE (1983) Single-and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm 2:139–143
Study RE, Barker JL (1982) Cellular mechanisms of benzodiazepine action. JAMA 247:2147–2151
Tedeschi G, Smith AT, Dhillon S, Richens A (1983) Rate of entrance of benzodiazepines into the brain determined by eye movement recording. Br J Clin Pharmacol 15:103–107
Walker JE, Homan RW, Vasko MR, Crawford IL, Bell RD, Tasker WG (1979) Lorazepam in status epilepticus. Ann Neurol 6:207–213
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, R.B., Kroboth, P.D., Vanderlugt, J.T. et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84, 452–456 (1984). https://doi.org/10.1007/BF00431449
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431449